Department of Economics, Thompson Rivers University, Kamloops, Canada.
Independent Researcher, Kagawa-ken, Japan.
Nicotine Tob Res. 2020 Aug 24;22(9):1646-1649. doi: 10.1093/ntr/ntaa121.
This ecological study investigates the association between smoking prevalence and COVID-19 occurrence and mortality in 38 European nations as of May 30, 2020.
Data were collected from Our World in Data. Regression analysis was conducted to adjust for potential confounding factors such as economic activity (gross domestic product), the rate of COVID-19 testing, and the stringency of COVID-19 control policies.
There was a statistically significant negative association between smoking prevalence and the prevalence of COVID-19 across the 38 European nations after controlling for confounding factors (p = 0.001). A strong association was found between the prevalence of COVID-19 per million people and economic activity (p = 0.002) and the rate of COVID-19 testing (p = 0.0006). Nations with stricter policy enactment showed fewer COVID-19 cases per million people, but the association was not significant (p = 0.122). Delaying policy enactment was associated with a greater prevalence of COVID-19 (p = 0.0535). Evidence of a direct association between smoking prevalence and COVID-19 mortality was not found (p = 0.626). There was a strong positive association between COVID-19 mortality rate and the prevalence of COVID-19 cases (p < 0.0001) as well as the proportion of the population over 65 years of age (p = 0.0034) and a negative association with the rate of COVID-19 testing (p = 0.0023).
We found a negative association between smoking prevalence and COVID-19 occurrence at the population level in 38 European countries. This association may not imply a true or causal relationship, and smoking is not advocated as a prevention or treatment of COVID-19.
Given the evidence of this ecological study, and of several other studies that found an underrepresentation of smoking prevalence in hospitalized cases, it may be worth examining, in laboratory experiments and controlled human trials, if nicotine offers any protection against COVID-19. Most importantly, to date, no study, including this one, supports the view that smoking acts as a treatment intervention or prophylaxis to reduce the impact or ameliorate the negative health impacts of COVID-19.
本生态研究调查了截至 2020 年 5 月 30 日,38 个欧洲国家的吸烟率与 COVID-19 发生和死亡率之间的关联。
数据来自 Our World in Data。进行回归分析以调整潜在的混杂因素,如经济活动(国内生产总值)、COVID-19 检测率和 COVID-19 控制政策的严格程度。
在控制了混杂因素后,38 个欧洲国家的吸烟率与 COVID-19 流行率之间存在统计学上的显著负相关(p=0.001)。每 100 万人 COVID-19 流行率与经济活动(p=0.002)和 COVID-19 检测率(p=0.0006)之间存在很强的关联。政策实施更严格的国家每 100 万人 COVID-19 病例较少,但关联不显著(p=0.122)。延迟政策实施与 COVID-19 流行率增加相关(p=0.0535)。没有发现吸烟率与 COVID-19 死亡率之间存在直接关联的证据(p=0.626)。COVID-19 死亡率与 COVID-19 病例流行率(p<0.0001)、65 岁以上人口比例(p=0.0034)呈强正相关,与 COVID-19 检测率(p=0.0023)呈负相关。
我们在 38 个欧洲国家的人群水平上发现吸烟率与 COVID-19 发生之间存在负相关。这种关联可能并不意味着真实或因果关系,也不提倡将吸烟作为 COVID-19 的预防或治疗方法。
鉴于本生态研究以及其他几项研究的证据表明,住院病例中吸烟率的代表性不足,因此在实验室实验和对照人体试验中,有必要研究尼古丁是否对 COVID-19 提供任何保护。最重要的是,迄今为止,包括本研究在内,没有一项研究支持吸烟作为治疗干预或预防措施来减轻 COVID-19 的影响或改善其对健康的负面影响的观点。